A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMA

Project: Research project

Description

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB (MPDL3280A, ANTI PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN OR CISPLATIN PEMETREXED COMPARED WITH CARBOPLATIN OR CISPLATIN PEMETREXED IN PATIENTS WHO ARE CHEMOTHERAPY-NAIVE AND
StatusActive
Effective start/end date2/1/1612/31/20

Funding

  • Genentech Inc.

Fingerprint

Pemetrexed
Carboplatin
Cisplatin
Drug Therapy
Antibodies
MPDL3280A